Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807871 · ClinicalTrials.gov registry record · Phase 4
Treatment of Smoking Lapses and Relapses
A Phase 4 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 4
- Development phase
- 701
- Enrollment target
NCT01807871 is a Phase 4 study that has completed, run by University of Vermont. The registered enrollment target is 701 participants.
The verdict
NCT01807871, a Phase 4 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 701 participants
- Enrollment target
Study Summary
Many smokers who try to stop smoking with nicotine medications (NM) such as gum, lozenge and patch, go back to smoking (i.e., a slip or lapse). Currently, labeling on many NM products tells smokers who lapse while using NM to stop NM. However, some studies suggest it is safe to continue NM upon a lapse and that doing so dramatically increases success at quitting. The investigators will test this by doing a randomized trial in which all treatment and measures are done from home with paper, phone or computer surveys. The investigators will recruit smokers who want to quit, provide them with 10 weeks of nicotine patch treatment and 5 weeks of counseling. One group will be asked to stop use of the patch if they lapse and the other group will be asked to continue use of the patch if they lapse. The investigators will compare the groups on their success at quitting and side-effects.
Interventions
- DRUG nicotine patch, experimental use
- DRUG nicotine patch, labeled use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807871
The ClinicalTrials.gov registry entry for NCT01807871 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 701 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nicotine patch, experimental use is the first listed.
NCT01807871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807871 about?
NCT01807871 is a clinical study titled "Treatment of Smoking Lapses and Relapses". Many smokers who try to stop smoking with nicotine medications (NM) such as gum, lozenge and patch, go back to smoking (i.e., a slip or lapse). Currently, labeling on many NM products tells smokers who lapse while using NM to stop NM. However, some studies suggest it is safe to continue NM upon a la...
What is the current status of trial NCT01807871?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 701 participants. The study started on 2013-03. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01807871?
The interventions under investigation include: nicotine patch, experimental use (DRUG), nicotine patch, labeled use (DRUG).
Who is sponsoring clinical trial NCT01807871?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.